V
39.15
2.44 (6.65%)
Penutupan Terdahulu | 36.71 |
Buka | 36.40 |
Jumlah Dagangan | 849,757 |
Purata Dagangan (3B) | 779,804 |
Modal Pasaran | 3,034,109,440 |
Harga / Pendapatan (P/E Ke hadapan) | 45.87 |
Harga / Jualan (P/S) | 7.33 |
Harga / Buku (P/B) | 2.69 |
Julat 52 Minggu | |
Tarikh Pendapatan | 6 Nov 2024 |
Margin Keuntungan | -2.18% |
Margin Operasi (TTM) | 10.53% |
EPS Cair (TTM) | -0.130 |
Pertumbuhan Hasil Suku Tahunan (YOY) | 28.60% |
Jumlah Hutang/Ekuiti (D/E MRQ) | 1.68% |
Nisbah Semasa (MRQ) | 5.07 |
Aliran Tunai Operasi (OCF TTM) | 66.12 M |
Aliran Tunai Bebas Leveraj (LFCF TTM) | 57.26 M |
Pulangan Atas Aset (ROA TTM) | 1.07% |
Pulangan Atas Ekuiti (ROE TTM) | -0.83% |
Arah Aliran Pasaran
Jangka Pendek | Jangka Sederhana | ||
Industri | Diagnostics & Research (US) | Bercampur | Bercampur |
Diagnostics & Research (Global) | Bercampur | Bercampur | |
Stok | Veracyte, Inc. | Menaik | Menaik |
AISkor Stockmoo
-0.5
Konsensus Penganalisis | 1.5 |
Aktiviti Orang Dalam | NA |
Volatiliti Harga | -0.5 |
Purata Bergerak Teknikal | -2.5 |
Osilator Teknikal | -0.5 |
Purata | -0.50 |
Veracyte Inc is a genomic diagnostics company. It provides genomic diagnostic products and services to improve patient care against diseases such as thyroid cancer, lung cancer, and idiopathic pulmonary fibrosis. The firm's product portfolio consists of products such as Afirma analysis, Percepta, Envisia, and others. |
|
Sektor | Healthcare |
Industri | Diagnostics & Research |
Gaya Pelaburan | Small Growth |
% Dimiliki oleh Orang Dalam | 0.79% |
% Dimiliki oleh Institusi | 104.38% |
Julat 52 Minggu | ||
Julat Harga Sasaran | ||
Tinggi | 46.00 (UBS, 17.50%) | Beli |
Median | 40.00 (2.17%) | |
Rendah | 28.00 (Morgan Stanley, -28.48%) | Jual |
Purata | 39.86 (1.81%) | |
Jumlah | 5 Beli, 1 Pegang, 1 Jual | |
Harga Purata @ Panggilan | 36.76 |
Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
---|---|---|---|---|
Goldman Sachs | 05 Dec 2024 | 37.00 (-5.49%) | Pegang | 42.84 |
07 Nov 2024 | 38.00 (-2.94%) | Beli | 37.34 | |
Morgan Stanley | 18 Nov 2024 | 28.00 (-28.48%) | Jual | 36.71 |
Scotiabank | 08 Nov 2024 | 44.00 (12.39%) | Beli | 36.48 |
Needham | 07 Nov 2024 | 44.00 (12.39%) | Beli | 37.34 |
UBS | 07 Nov 2024 | 46.00 (17.50%) | Beli | 37.34 |
16 Oct 2024 | 43.00 (9.83%) | Beli | 34.72 | |
Leerink Partners | 17 Oct 2024 | 40.00 (2.17%) | Beli | 34.31 |
Guggenheim | 10 Oct 2024 | 40.00 (2.17%) | Beli | 32.27 |
Tiada data dalam julat masa ini.
Tarikh | Jenis | Butiran |
---|---|---|
05 Dec 2024 | Pengumuman | Veracyte’s Decipher Prostate Test Is Now the Only Gene Expression Test Recommended in NCCN® Prostate Cancer Guidelines |
06 Nov 2024 | Pengumuman | Veracyte Announces Third Quarter 2024 Financial Results |
30 Oct 2024 | Pengumuman | Veracyte to Participate in Upcoming Investor Conferences |
16 Oct 2024 | Pengumuman | Veracyte to Release Third Quarter 2024 Financial Results on November 6, 2024 |
02 Oct 2024 | Pengumuman | New Data Presented at ASTRO 2024 Show that Veracyte’s Decipher Prostate Test Predicts Aggressive Prostate Cancer in African American Men |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
Keuntungan Nyata | - |
Keuntungan Tidak Nyata | - |
Dividen Diterima 2024 | - |
Jumlah Untung | - |
Pulangan Purata | - |
Kuantiti (Beli) | - |
Purata Harga (Beli) | - |
Kuantiti (Jual) | - |
Purata Harga (Jual) | - |